MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2022-04-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to confirm the safety and tolerability of elranatamab
(PF-06863135) in Japanese participants with relapsed or refractory MM.